Pre-operative plasma levels of C-reactive protein, albumin and various plasma protease inhibitors for the pre-operative assessment of operability and recurrence in cancer surgery

European Journal of Surgical Oncology

Volumn 22, Issue 6, 1996, Pages 607-617

  Göransson, Joakim ^a   Jonsson, Svante ^a   Lasson, Åke ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

C reactive protein; Cancer; Plasma protease inhibitors; Surgery

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ALPHA 2 MACROGLOBULIN; ANTITHROMBIN III; C REACTIVE PROTEIN; CARCINOEMBRYONIC ANTIGEN; COMPLEMENT COMPONENT C1S INHIBITOR; HEMOGLOBIN; PROTEINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CONTROLLED STUDY; FOLLOW UP; HUMAN; INOPERABLE CANCER; MAJOR CLINICAL STUDY; METASTASIS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SOLID TUMOR;

EID: 0030478870     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0748-7983(96)92398-7     Document Type: Article

References (60)

1. Ihse I, Gibson RN, Boyce HW, Lees WR, Van Sonnenberg E. Working party report to the world congresses of gastroenterology, Sydney 1990. The role of imaging in the non-operative staging of gastrointestinal tumours. J Gastroenterol Hepatol 1979; 6: 423-41.
2. Niederau C, Grendell JH. Diagnosis of pancreatic carcinoma. Imaging techniques and tumor markers. Pancreas 1992; 1: 66-86.
3. Tumour staging in gastrointestinal tumours. Endoscopy 1993; 25: 1-142.
4. Neville AM, Cooper EH. Biochemical monitoring of cancer. Ann Clin Biochem 1976; 13: 283-305.
5. Roberts PJ. Clinical value of tumour markers. Ann Chir Gyn 1989; 78: 1-82.
6. Woolfson K. Tumor markers in cancer of the colon and rectum. Dis Colon Rectum 1991; 34: 506-11.
7. Eskelinen M, Pasanen P, Kulju A, et al. Clinical evaluation of serum tumour markers CEA, CA 50 and CA 242 in colorectal cancer. Anticancer Res 1994; 14: 1427-32.
8. Hollinshead AC, Chuang C-Y, Cooper EH, Catalona WJ. Interrelationship of prealbumin and alpha-1 acid glycoprotein in cancer patient sera. Cancer 1977; 40: 2993-8.
9. Ward AM, Cooper EH, Turner R, Anderson JA, Neville AM. Acute-phase reactant protein profiles: an aid to monitoring large bowel cancer by CEA and serum enzymes. Br J Cancer 1977; 35: 170-8.
10. Milano G, Cooper EH, Goliher JC, Giles GR, Neville AM. Serum prealbumin, retinol-binding protein, transferrin, and albumin levels in patients with large bowel cancer. J Natl Cancer Inst 1978; 61: 687-91.
11. Bastable JRG, Richards B, Haworth S, Cooper EH. Acute phase reactant proteins in the clinical management of carcinoma of the bladder. Br J Urol 1979; 51: 283-9.
12. Cooper EH, Stone J. Acute phase reactant proteins in cancer. Adv Cancer Res 1979; 30: 1-44.
13. Velde ER, Berrens L, Zegers BJM, Ballieux RE. Acute phase reactants and complement components as indicators of recurrence in human cervical cancer. Eur J Cancer 1979; 15: 893-9.
14. Trautner K, Cooper EH, Haworth S, Ward AM. An evaluation of serum protein profiles in the long-term surveillance of prostatic cancer. Scand J Urol Nephrol 1980; 14: 143-9.
15. Drahovsky D, Dunzendorfer U, Ziegenhagen G, Drahovsky M, Kellen JA. Reevaluation of C-reactive protein in cancer sera by radioimmunoassay and radial immunodiffusion. Oncology 1981; 38: 286-91.
16. O'Quigley J, Haworth S, Cooper EH, Haije W, van der Werf-Messing B, Richards B, Robinson MRG. Prognostic significance of serum proteins in invasive bladder cancer. Eur J Cancer 1981; 17: 251-5.
17. Richards B, Robinson MRG, Pidcock NB, Cooper EH. Serum protein profiles in carcinoma of the kidney. Eur Urol 1982; 8: 32-6.
18. de Mello J, Struthers L, Turner R, Cooper EH, Giles GR, and the Yorkshire Regional Gastrointestinal Cancer Research Group. Multivariate analyses as aids 'to diagnosis and assessment of prognosis in gastrointestinal cancer. Br J Cancer 1983; 48: 341-8.
19. Raynes JG, Cooper EH. Comparison of serum amyloid A protein and C-reactive protein concentrations in cancer and non-malignant disease. J Clin Pathol 1983; 36: 798-803.
20. Walker C, Gray BN. Acute-phase reactant proteins and carcinoembryonic antigen in cancer of the colon and rectum. Cancer 1983; 52: 150-4.
21. Durdey P, Williams NS, Brown DA. Serum carcinoembryonic antigen and acute phase reactant proteins in the pre-operative detection of fixation of colorectal tumours. Br J Surg 1984; 71: 881-4.
22. Ganz PA, Baras M, Ma PY, Elashoff RM. Monitoring the therapy of lung cancer with alpha-1-acid glycoprotein. Cancer Res 1984; 44: 5415-21.
23. Weinstein PS, Skinner M, Sipe JD, Lokich JJ, Zamchek N, Cohen AS. Acute-phase proteins or tumor markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases. Scand J Immunol 1984; 19: 193-8.
24. Büchler M, Malfertheiner P, Uhl W, Beger HG. C-reaktives Protein als Entzündungs- und Nekrosemarker in der Gastroenterologi. Med Klin 1987; 82: 180-5.
25. Göransson J, Lasson A. Plasma levels of C-reactive protein in the diagnosis of acute abdominal disease. Surg Res Comm 1991; 11: 107-18.
26. Åvall Lundqvist E, Blad E, Xiao L, Sjövall K, Eneroth P. Pretreatment serum levels of C-reactive protein, alpha-1-antitrypsin, haptoglobin, alpha-1-acid glycoprotein and tissue polypeptide antigen in cervical carcinoma. Eur J Gynaec Oncol 1991; 12: 375-83.
27. Ballou SP, Kushner I. C-reactive protein and the acute phase response. Adv Intern Med 1992; 37: 313-36.
28. Lasson Å, Berling R, Göransson J. Plasma CRP-levels in the diagnosis of postoperative complications. Surg Res Comm 1992; 12: 203-11.
29. Stamatiadis AP, Manouras AJ, Triantes GN, Katergiannakis VA, Apostolidis NS. Combination of serum carcino-embryonic antigen and C-reactive protein - a useful test in preoperative staging of colorectal cancer. Eur J Surg Oncol 1992; 18: 41-3.
30. Fuchs D, Weiss G, Reibnegger G, Wachter H. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant disease. Crit Rev Clin Lab Sci 1992; 29: 307-41.
31. Blay J-Y, Negrier S, Combaret V, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992; 52: 3317-22.
32. Barch-Mortensen N, Osther K, Stroyer I. C1-esterase inactivators and C4 in malignant disease. Lancet 1975; 13: 499-500.
33. Astrup J, Colstrup H, Frandsen B. Complement C1-inactivator in the serum of patients with malignant disease. Acta Radiol Ther Phys Biol 1977; 16: 394-400.
34. Janssen CW, Tönder O, Matre R. Stage-related correlations between immunoglobulins and complement components in preoperative sera from patients with gastric carcinoma. Eur J Cancer Clin Oncol 1983; 19: 1601-5.
35. Janssen CW, Maartmann-Moe H, Lie RT. Preoperative prediction of extent and prognosis of gastric carcinoma by four serum proteins and erythrocyte sedimentation rate. Eur J Surg Oncol 1987; 13: 285-95.
36. Janssen CW, Lie RT, Maartmann-Moe H, Matre R. Who gets a second primary cancer after gastric cancer surgery? Eur J Surg Oncol 1990; 16: 195-9.
37. Janssen CW, Lie RT, Bassøe C-F, Maartmann-Moe H, Matre R. The influence of the host on the course of gastric carcinoma. Br J Cancer 1992; 66: 870-4.
38. Starcevic D, Jelic-Ivanovic Z, Kalimanovska V. Plasma C1 inhibitor in malignant diseases: Functional activity versus concentration. Ann Clin Biochem 1991; 28: 595-8.
39. Roeise O, Siversten S, Ruud TE, Bouma BN, Stadaas JO, Aasen AO. Studies on components of the contact phase system. in patients with advanced gastrointestinal cancer. Cancer 1990; 65: 1355-9.
40. Ades EW, Hinson A, Chapius-Cellier C, Arnaud P. Modulation of the immune response by plasma protease inhibitors. Scand J Immunol 1982; 15: 109-13.
41. Donnelly PK, Shenton BK, Alomran AM, Francis DMA, Proud G, Taylor RMR. The role of protease in immunoregulation. Br J Surg 1983; 70: 614-22.
42. Taylor AW, Mortensen RF. Effect of alpha-2-macroglobulin on cytokine-mediated human C-reactive protein production. Inflammation 1991; 15: 61-70.
43. Borth W. Alpha-2-macroglobulin. A multifunctional binding and targeting protein with possible roles in immunity and autoimmunity. Ann NY Acad Sci 1994; 267-72.
44. Broom J, Heys SD, Whiting PH, et al. Interleukin 2 therapy in cancer; identification of responders. Br J Cancer 1992; 66: 1185-7.
45. Hermanek P, Sobin LH (eds). TNM. Classification of Malignant Tumours (4th edn). Berlin, Heidelberg, New York, London, Paris, Tokyo: Springer-Verlag, 1987.
46. Turnbull RB Jr. Cancer of the colon: the influence of the no-touch isolation technic on survival rates. Ann Surg 1967; 166: 420-7.
47. Pettersson F (ed). Annual Report on the Results of Treatment in Gynecological Cancer, Vol. 22. Repro Print: Sweden, 1995.
48. Laurell CB. Electroimmunoassay. Scand J Clin Lab Invest 1972; 29 (Suppl. 124): 21-37.
49. Friberger P. Chromogenic peptide substrates. Their use for the assay of factors in the fibrinolytic and the plasma kallikrein-kinin systems. Scand J Clin Lab Invest 1982; 42 (Suppl. 162): 84-9.
50. Snedecor GW, Cochran WG (ed). Statistical Methods (7th edn). Ames: The Iowa State University Press, 1982.
51. Osther K. C1 inactivator from cancer cells. Lancet 1974; 2: 359-60.
52. Coombes RC, Gazet JC, Sloane JP, Powles TJ, Ford HT, Laurence DJR, Neville AM. Biochemical markers in human breast cancer. Lancet 1977; 15: 132-4.
53. Hillyard JW, Keyser JW, Newcombe RG, et al. Biochemical aids to the staging of breast cancer. Clin Biochem 1982; 15: 9-12.
54. Robertson JFR, Pearson D, Price MR, Selby C, Pearson J, Blamey RW, Howell A. Prospective assessment of the role of five tumour markers in breast cancer. Cancer Immunol Immunother 1991; 33: 403-10.
55. Chisholm EM, Marshall RJ, Brown D, Cooper EH, Giles GR. The role of a questionnaire and four biochemical markers to detect cancer risk in a symptomatic population. Br J Cancer 1986; 53: 53-7.
56. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and p-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992; 80: 733-7.
57. San F, Link KH, Beger HG. Is follow-up of colorectal cancer patients worthwhile? Dis Colon Rectum 1993; 36: 636-44.
58. Vernava III AM, Longo WE, Virgo KS, Coplin MA, Wade TP, Johnson FE. Current follow-up strategies after resection of colon cancer. Result of a survey of members of the American Society of Colon and Rectal Surgeons. Dis Colon Rectum 1994; 37: 573-83.
59. Lindmark G, Gerdin B, Påhlman L, Bergström R, Glimelius B. Prognostic predictors in colorectal cancer. Dis Colon Rectum 1994; 37: 1219-27.
60. Moertel CG, O'Fallon JR, Go VLW, O'Connell MJ, Thynne GS. The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer 1986; 58: 603-10.